Transthyretin Amyloidosis Treatment Market Growth, Trends and Forecast 2034
Global Transthyretin Amyloidosis Treatment Market Growth, Size, Trends Analysis- By Therapy, By Type, By Disease, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25204 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
Global Transthyretin Amyloidosis Treatment Market Introduction and Overview
According to SPER Market Research, the Global Transthyretin Amyloidosis Treatment Market is estimated to reach USD 24979.79 million by 2034 with a CAGR 14.16%.
The report includes an in-depth analysis of the Global Transthyretin Amyloidosis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. With an increasingly aging population, the occurrence of this rare and complex disease is on the rise. This demographic change underscores the urgent need for effective therapies to manage its debilitating symptoms and prevent further progression. Market growth is driven by advances in drug development, with companies like AstraZeneca and Alnylam introducing treatments such as Eplontersen and AMVUTTRA for transthyretin amyloidosis. Ongoing research and clinical trials reflect growing optimism for improved therapies. Increased awareness and better diagnostics enable earlier detection and timely intervention, boosting treatment adoption. Favorable reimbursement policies, especially in North America, enhance access to these costly therapies. Additionally, collaboration between research institutions and pharmaceutical companies supports the development of targeted treatments, further expanding options for patients and contributing to overall market expansion.
By Therapy:
Targeted therapy leads the market due to the proven effectiveness of treatments like tafamidis and patisiran, which directly address the root causes of the disease, improve patient outcomes, and slow its progression—driving strong demand among healthcare providers. Looking ahead, pipeline therapies are expected to see significant growth, supported by advances in drug development and clinical research. Ongoing trials aim to improve treatment efficacy and reduce side effects, offering new hope for patients with both hereditary and wild-type forms of the disease.
By Type:
ATTR with Polyneuropathy (ATTR-PN) currently dominates the market, driven by its higher prevalence and the severity of neurological symptoms that require effective management. Increased awareness and advancements in treatment have led healthcare providers to focus more on therapies targeting polyneuropathy. Meanwhile, ATTR with Cardiomyopathy (ATTR-CM) is projected to experience the fastest growth, fueled by improved diagnostic tools and rising recognition of its symptoms. As understanding deepens, demand for targeted cardiomyopathy treatments is expected to increase substantially over the coming years.
By Disease:
Wild-type amyloidosis leads the market, driven by improved recognition and diagnosis, especially among older adults who are more susceptible. This has led to a higher incidence and growing demand for effective treatments. Advances in disease understanding and the availability of targeted therapies have also strengthened healthcare providers' ability to manage this form confidently. Meanwhile, hereditary transthyretin amyloidosis is expected to grow rapidly, fueled by increased genetic testing and awareness efforts, along with research into gene-silencing therapies that are expanding treatment possibilities.
By Distribution Channel:
Hospital pharmacies led the market, largely due to their vital role in delivering specialized medications and comprehensive care for patients with rare conditions like transthyretin amyloidosis. Their expertise in handling complex therapies enables them to offer personalized treatment approaches. Additionally, hospital pharmacies work closely with healthcare professionals to monitor patient progress and make necessary adjustments to treatment plans, ensuring optimal outcomes.
Regional Insights:
North America led the global transthyretin amyloidosis treatment market, driven by rising awareness, supportive reimbursement policies, and the availability of innovative therapies that promote greater patient engagement. Strong partnerships between pharmaceutical companies and research institutions are fueling ongoing innovation, improving patient outcomes, and solidifying the region’s leadership in the global market.
Market Competitive Landscape:
The global Transthyretin Amyloidosis Treatment Market is moderately consolidated, with several prominent players shaping the industry. Key companies include: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, AstraZeneca, Akcea Therapeutics, BridgeBio Inc., Intellia Therapeutics, Inc., SOM BIOTECH, Oncopeptides AB, Takeda Pharmaceutical Company Limited.
Recent Developments:
In November 2024, Alnylam Pharmaceuticals announced that the FDA had accepted its supplemental New Drug Application for vutrisiran as a treatment for ATTR amyloidosis with cardiomyopathy, with a PDUFA decision date scheduled for March 23, 2025.
In October 2024, Wainzua (eplontersen) received a positive recommendation from the EU CHMP for the treatment of hereditary transthyretin-mediated amyloidosis, showing sustained improvements in neuropathy and quality of life compared to placebo in Phase III trials.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Therapy, By Type, By Disease, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, AstraZeneca, Akcea Therapeutics, BridgeBio Inc., Intellia Therapeutics, Inc., SOM BIOTECH, Oncopeptides AB, Takeda Pharmaceutical Company Limited. |
Key Topics Covered in the Report
- Global Transthyretin Amyloidosis Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Transthyretin Amyloidosis Treatment Market
- Segmentation of Global Transthyretin Amyloidosis Treatment Market By Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy)
- Segmentation of Global Transthyretin Amyloidosis Treatment Market By Type {(ATTR with Polyneuropathy (ATTR-PN), ATTR with Cardiomyopathy (ATTR-CM)}
- Segmentation of Global Transthyretin Amyloidosis Treatment Market By Disease (Hereditary Transthyretin Amyloidosis, Wild Type Amyloidosis)
- Segmentation of Global Transthyretin Amyloidosis Treatment Market By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
- Statistical Snap of Global Transthyretin Amyloidosis Treatment Market
- Expansion Analysis of Global Transthyretin Amyloidosis Treatment Market
- Problems and Obstacles in Global Transthyretin Amyloidosis Treatment Market
- Competitive Landscape in the Global Transthyretin Amyloidosis Treatment Market
- Details on Current Investment in Global Transthyretin Amyloidosis Treatment Market
- Competitive Analysis of Global Transthyretin Amyloidosis Treatment Market
- Prominent Players in the Global Transthyretin Amyloidosis Treatment Market
- SWOT Analysis of Global Transthyretin Amyloidosis Treatment Market
- Global Transthyretin Amyloidosis Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Transthyretin Amyloidosis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Transthyretin Amyloidosis Treatment Market
7.Global Transthyretin Amyloidosis Treatment Market, By Therapy, (USD Million) 2021-2034
7.1.Targeted Therapy
7.1.1.Vyndaqel/ Vyndamax7.1.2.Onpattro7.1.3.Amvuttra7.1.4.Tegsedi7.1.5.Wainua
7.2.Supportive Therapy7.3.Pipeline Therapy
8.Global Transthyretin Amyloidosis Treatment Market, By Type, (USD Million) 2021-2034
8.1.ATTR with Polyneuropathy (ATTR-PN)8.2.ATTR with Cardiomyopathy (ATTR-CM)
9.Global Transthyretin Amyloidosis Treatment Market, By Disease, (USD Million) 2021-2034
9.1.Hereditary Transthyretin Amyloidosis
9.1.1.Polyneuropathy9.1.2.Cardiomyopathy9.1.3.Mixed Type
9.2.Wild Type Amyloidosis
10.Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, (USD Million) 2021-2034
10.1.Hospital Pharmacies10.2.Specialty Pharmacies10.3.Retail Pharmacies10.4.Online Pharmacies
11.Global Transthyretin Amyloidosis Treatment Market, (USD Million) 2021-2034
11.1.Global Transthyretin Amyloidosis Treatment Market Size and Market Share
12.Global Transthyretin Amyloidosis Treatment Market, By Region, 2021-2034 (USD Million)
12.1.Asia-Pacific
12.1.1.Australia12.1.2.China12.1.3.India12.1.4.Japan12.1.5.South Korea12.1.6.Rest of Asia-Pacific
12.2.Europe
12.2.1.France12.2.2.Germany12.2.3.Italy12.2.4.Spain12.2.5.United Kingdom12.2.6.Rest of Europe
12.3.Middle East and Africa
12.3.1.Kingdom of Saudi Arabia12.3.2.United Arab Emirates12.3.3.Qatar12.3.4.South Africa12.3.5.Egypt12.3.6.Morocco12.3.7.Nigeria12.3.8.Rest of Middle-East and Africa
12.4.North America
12.4.1.Canada12.4.2.Mexico12.4.3.United States
12.5.Latin America
12.5.1.Argentina12.5.2.Brazil12.5.3.Rest of Latin America
13.Company Profile
13.1.Pfizer Inc.
13.1.1.Company details13.1.2.Financial outlook13.1.3.Product summary13.1.4.Recent developments
13.2.Alnylam Pharmaceuticals, Inc.
13.2.1.Company details13.2.2.Financial outlook13.2.3.Product summary13.2.4.Recent developments
13.3.Ionis Pharmaceuticals
13.3.1.Company details13.3.2.Financial outlook13.3.3.Product summary13.3.4.Recent developments
13.4.AstraZeneca
13.4.1.Company details13.4.2.Financial outlook13.4.3.Product summary13.4.4.Recent developments
13.5.Akcea Therapeutics
13.5.1.Company details13.5.2.Financial outlook13.5.3.Product summary13.5.4.Recent developments
13.6.BridgeBio Inc.
13.6.1.Company details13.6.2.Financial outlook13.6.3.Product summary13.6.4.Recent developments
13.7.Intellia Therapeutics, Inc.
13.7.1.Company details13.7.2.Financial outlook13.7.3.Product summary13.7.4.Recent developments
13.8.SOM BIOTECH
13.8.1.Company details13.8.2.Financial outlook13.8.3.Product summary13.8.4.Recent developments
13.9.Oncopeptides AB
13.9.1.Company details13.9.2.Financial outlook13.9.3.Product summary13.9.4.Recent developments
13.10.Takeda Pharmaceutical Company Limited
13.10.1.Company details13.10.2.Financial outlook13.10.3.Product summary13.10.4.Recent developments
13.11.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The report includes an in-depth analysis of the Global Transthyretin Amyloidosis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
Transthyretin Amyloidosis Treatment Market is projected to reach USD 24979.79 million by 2034, growing at a CAGR of of 14.16% during the forecast period.
Transthyretin Amyloidosis Treatment Market grew in Market size from 2025. The Market is expected to reach USD 24979.79 million by 2034, at a CAGR of 14.16% during the forecast period.
Transthyretin Amyloidosis Treatment Market CAGR of 14.16% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Transthyretin Amyloidosis Treatment Market size is USD 24979.79 million from 2025 to 2034.
Transthyretin Amyloidosis Treatment Market is covered By Therapy, By Type, By Disease, By Distribution Channel
The North America is anticipated to have the highest Market share in the Transthyretin Amyloidosis Treatment Market.
Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, AstraZeneca, Akcea Therapeutics, BridgeBio Inc., Intellia Therapeutics, Inc., SOM BIOTECH, Oncopeptides AB, Takeda Pharmaceutical Company Limited.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
